Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds
- PMID: 12452937
- DOI: 10.1046/j.1365-2036.2002.01375.x
Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds
Abstract
Background: Poor compliance with 5-aminosalicylic acid therapy has been reported amongst patients with inflammatory bowel disease. Currently, there is no easy method to monitor 5-aminosalicylic acid; however, the chemical similarity between 5-aminosalicylic acid and salicylate might provide a solution.
Aim: To determine the feasibility of using salicylate levels to monitor compliance with 5-aminosalicylic acid medication.
Methods: Thirty-six patients with inflammatory bowel disease, taking maintenance 5-aminosalicylic acid, provided either a paired serum and urine sample or an intestinal biopsy. Samples were split into two: half were sent to the hospital biochemistry department for salicylate measurement, and half were analysed for 5-aminosalicylic acid and its metabolite, N-acetyl-5-aminosalicylic acid, using high performance liquid chromatography. Correlation between the results was calculated.
Results: Serum and urine were available for 25 patients. Serum salicylate was undetectable, but urinary salicylate ranged from 31 to 3254 microg/mL. The correlations between urinary salicylate and 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid were 0.96 (95% confidence interval, 0.91-0.98) and 0.9 (95% confidence interval, 0.77-0.96), respectively. Sixteen biopsies were available from 13 patients. The 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid concentrations were 0.2-657 ng/mg and 1.6-1598 ng/mg, respectively; there was no correlation with bowel salicylate.
Conclusions: The close correlation between 5-aminosalicylic acid and salicylate levels offers a simple method to assess compliance with 5-aminosalicylic acid therapy.
Similar articles
-
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2003 Jul 15;18(2):191-8. doi: 10.1046/j.1365-2036.2003.01648.x. Aliment Pharmacol Ther. 2003. PMID: 12869079
-
A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.Am J Gastroenterol. 2013 Feb;108(2):249-55. doi: 10.1038/ajg.2012.419. Epub 2013 Jan 8. Am J Gastroenterol. 2013. PMID: 23295279
-
Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.Aliment Pharmacol Ther. 2000 Sep;14(9):1169-79. doi: 10.1046/j.1365-2036.2000.00824.x. Aliment Pharmacol Ther. 2000. PMID: 10971234
-
Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.Drug Dev Ind Pharm. 2011 Sep;37(9):1100-9. doi: 10.3109/03639045.2011.560156. Epub 2011 Mar 21. Drug Dev Ind Pharm. 2011. PMID: 21417610 Review.
-
5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?Nephrol Dial Transplant. 1997 Sep;12(9):1839-41. doi: 10.1093/ndt/12.9.1839. Nephrol Dial Transplant. 1997. PMID: 9306332 Review. No abstract available.
Cited by
-
Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.World J Gastroenterol. 2010 Feb 7;16(5):578-82. doi: 10.3748/wjg.v16.i5.578. World J Gastroenterol. 2010. PMID: 20128025 Free PMC article.
-
Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.Br J Clin Pharmacol. 2018 Mar;84(3):477-481. doi: 10.1111/bcp.13462. Epub 2017 Dec 6. Br J Clin Pharmacol. 2018. PMID: 29073323 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources